Stock 4579 RAQUALIA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News RaQualia Pharma Inc.

Equities

4579

JP3967150008

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
595 JPY -1.49% Intraday chart for RaQualia Pharma Inc. +0.68% -13.52%
Mar. 26 RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others. CI
Feb. 14 RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.
CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024
CI
RaQualia Pharma Inc. agreed to acquire FIMECS, Inc. from Nissay Capital No. 11 Investment Limited Partnership and Nissay Capital Co., Ltd. for ¥4.5 billion.
CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
CI
Constipation Pipeline, Clinical Trials, and Key Companies|Companies-Anji Pharma, Yuhan, Theravance Biopharma
AQ
RaQualia Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
RaQualia Pharma Inc. announced that it has received ¥805.6125 million in funding from CVI Investments, Inc.
CI
RaQualia Pharma Inc. announced that it expects to receive Ñ805.6125 million in funding from CVI Investments, Inc.
CI
Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for Year Ending December 31, 2022
CI
RaQualia Pharma : Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (JGAAP)
PU
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
CI
RaQualia Pharma : (Delayed)Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (JGAAP)
PU
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022
CI
RaQualia Pharma Inc. Provides Earnings Guidance for the Year Ending December 31, 2021
CI
Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2021
CI
RaQualia Pharma Inc. Announces Consolidated Financial Results for the Six Months Ended June 30, 2021
CI
RaQualia Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2021
CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4579 Stock
  4. News RaQualia Pharma Inc.